Long-term outcome results of the first tandem autotransplant trial for multiple myelomaBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Br J Haematol 135:158-64. 2006
..038). Ten-year EFS and OS could be accomplished in 15% and 33% of patients, respectively, when all agents available in 1989, especially high-dose melphalan, were applied together upfront for the management of myeloma...
- Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning
Choon Kee Lee
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
Exp Hematol 31:73-80. 2003
..The aim of this study was to identify prognostic factors for outcome of high-risk patients with multiple myeloma after allogeneic transplantation prepared by reduced intensity conditioning (RIC)...
High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patientsMauricio Pineda-Roman
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Cancer 112:1754-64. 2008
..In this report, the authors describe their collective experience with melphalan-based autotransplants since the inception of their program at the University of Arkansas for Medical Sciences in 1989...
- Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
Bart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 138:176-85. 2007
..Results of this phase-2 study demonstrated that bortezomib could be safely combined with multi-agent chemotherapy, effecting near-complete remission status and 2-year survival rates in more than 80% of patients...
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myelomaLijuan Chen
The Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
Blood 115:61-70. 2010
..Consistently, JUN or EGR-1 knockdown in cultured MM cells enhanced their resistance to bortezomib, demonstrating the crucial role of low JUN/EGR-1 expression in MM resistance to bortezomib...
- DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma
Choon Kee Lee
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Slot 776, 4301 West Markham, Little Rock, AR 72205, USA
J Clin Oncol 21:2732-9. 2003
..To improve outcome in previously treated patients (at least two cycles of standard therapy) with multiple myeloma, thalidomide was combined with cytotoxic chemotherapy as induction therapy...
- Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival
Maurizio Zangari
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
Clin Lymphoma 4:32-5. 2003
..002), and creatinine level > or = 2 mg/dL (P < 0.001). However, the development of DVT did not adversely affect survival when examined as a time-dependent variable and adjusted for standard risk features (hazard ratio, 0.8; P = 0.162)...
- Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease
Angela Pennisi
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 145:775-87. 2009
..These data demonstrated that DASH proteases are involved in myeloma bone disease and tumour growth...
- High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2
Yiming Zhou
Donna D and Donald M Lambert Laboratory for Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Proc Natl Acad Sci U S A 107:7904-9. 2010
..Silencing of AGO2 dramatically decreased viability in MM cell lines. Genome-wide elevated expression of miRNAs in high-risk MM may be secondary to deregulation of AGO2 and the enzyme complexes that regulate miRNA maturation and function...
- Thalidomide and hematopoietic-cell transplantation for multiple myeloma
Bart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
N Engl J Med 354:1021-30. 2006
..High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed whether the addition of thalidomide, which has activity against advanced and refractory myeloma, would further improve survival...
- Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma
Ya Wei Qiang
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 112:196-207. 2008
....
- Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival
Bijay Nair
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
Blood 113:6572-5. 2009
..001). Based on its PRS predictive power, GEP analysis should be an integral part of new agent trials in search of better therapy for high-risk myeloma...
- Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
Bart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
Blood 112:3122-5. 2008
..Trial registered at http://www.clinicaltrials.gov under identifier NCT00083382...
- Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival
Yun Ge
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 133:83-92. 2006
..Our results indicate that FAP is critical for the interaction of MM cells with the BM microenvironment--a potential therapeutic target in myeloma...
- Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
Bijay Nair
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 115:4168-73. 2010
..The robustness of the GEP risk model should be exploited in clinical trials aimed at improving the notoriously poor outcome in high-risk disease...
- Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
Frits van Rhee
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 116:1220-7. 2010
....
- International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols
Sarah Waheed
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Cancer 117:1001-9. 2011
....
- Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease
Mauricio Pineda Roman
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 136:393-9. 2007
..In comparison with U-MM, E-MM evolved from MGUS/SMM was associated with lower CR rate without adversely affecting survival. In contrast, CR was an independent favourable feature for survival in U-MM...
- Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
Mauricio Pineda-Roman
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 140:625-34. 2008
..Our data strongly suggest that the addition of bortezomib in TT3 was accountable for its superior performance rather than greater compliance with protocol completion as a result of greater dose-density in TT3 vs. TT2...
- RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma
Siqing Wang
The Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR, USA
Blood 114:600-7. 2009
..These findings provide a rationale for RA-based therapy in aggressive RARalpha2(+) MM...
- F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
Twyla B Bartel
Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 114:2068-76. 2009
..Our results provide a rationale for testing the hypothesis that myeloma survival can be improved by altering treatment in patients in whom FDG suppression cannot be achieved after induction therapy...
- Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile
Yiming Zhou
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham 816, Little Rock, AR 72205, USA
Br J Haematol 145:637-41. 2009
..42, P = 0.004). The prevalence of high-risk myeloma in the RS+/FL+ group may reflect a dissemination-prone condition not shared by the other three groups...
- Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II
John Shaughnessy
Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 120:44-52. 2003
..02 and 0.1 respectively) and should be part of the initial work-up of patients with MM...
- Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321
Bart Barlogie
University of Arkansas for Medical Science, Little Rock, AR, USA
J Clin Oncol 24:929-36. 2006
..13). CONCLUSION: The HDT and SDT regimens used in S9321 yielded comparable response rates and PFS and OS durations. IFN maintenance therapy did not benefit patients who achieved > or = 75% tumor reduction on either arm...
- The molecular classification of multiple myeloma
Fenghuang Zhan
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 108:2020-8. 2006
..A subset of cases with a predominating myeloid gene expression signature, excluded from the profiling analyses, had more favorable baseline characteristics and superior prognosis to those lacking this signature...
- Treatment of multiple myeloma
Bart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 103:20-32. 2004
..Fundamental and clinical research should, therefore, focus on the molecular and biologic mechanisms of treatment failure in the high-risk subgroup...
- Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications
Ronald Walker
Department of Radiology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
J Clin Oncol 25:1121-8. 2007
..Magnetic resonance imaging (MRI) permits the detection of diffuse and focal bone marrow infiltration in the absence of osteopenia or focal osteolysis on standard metastatic bone surveys (MBSs)...
- Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989
Bart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR 72205, USA
Blood 111:94-100. 2008
..While the risk of MDS-CAs was low and clinical MDS occurred infrequently, monitoring after post-HDT consolidation chemotherapy appears warranted...
- Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies
Bart Barlogie
Medicine and Pathology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 107:2633-8. 2006
..The favorable effects of CR and rapidly sequenced second transplantation attest to the validity of a melphalan dose-response effect in myeloma...
- Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
Fenghuang Zhan
Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock 72205, USA
Blood 109:1692-700. 2007
..01). The MGUS-L signature was also seen in plasma cells from 15 of 20 patients surviving more than 10 years after autotransplantation. These data provide insight into the molecular mechanisms of plasma-cell dyscrasias...
- Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics
John D Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 137:530-6. 2007
....
- Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
Bart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
Blood 112:3115-21. 2008
..008). Because two thirds of patients without CAs have remained alive at 7 years, the presently emerging separation in favor of thalidomide may eventually reach statistical significance as well...
- TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3
John D Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 147:347-51. 2009
..FGFR3+ and FGFR3- molecular subgroups fared worse in the presence of del TP53 when applying TT2 but not TT3. Thus, the prognostic implications of del TP53 were protocol-, genome-defined risk- and molecular subgroup-dependent...
- Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients
Athanasios B T Fassas
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 119:164-8. 2002
..Other approaches may be required to improve survival in multiple myeloma...
- Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis
Elias J Anaissie
Myeloma Institute for Research and Therapy, Division of Supportive Care, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Cancer 118:549-57. 2012
..As a result, most patients receive thromboprophylaxis with low molecular weight heparin (LMWH). The purpose of this retrospective study was to identify risk factors for VTE in NDMM and evaluate the effectiveness of LMWH...
- Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy
Giampaolo Talamo
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
J Clin Oncol 23:5217-23. 2005
..CONCLUSION: AVN is a rare and usually asymptomatic complication during myeloma therapy. Cumulative dexamethasone dose, male sex, and younger age, but not thalidomide, increase the risk of AVN...
- Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma
Bart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
Clin Lymphoma Myeloma 6:469-74. 2006
..Complete response has been considered a surrogate for favorable long-term outcome in multiple myeloma. Data on the impact of the duration of response on prognosis are lacking...
- Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone
Xin Li
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Stem Cells 29:263-73. 2011
..This study suggests that altering the bone marrow microenvironment with PDAC cytotherapy attenuates growth of myeloma and that PDAC cytotherapy is a promising therapeutic approach for myeloma osteolysis...
- Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
Frits van Rhee
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock AR 72205, USA
Mol Cancer Ther 8:2616-24. 2009
....
- Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantatio
Ichiro Hanamura
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W. Markham St. #776, Little Rock, AR 72205, USA
Blood 108:1724-32. 2006
..027). The proportion of cells with Amp1q21 and the copy number of 1q21 tended to increase at relapse compared with diagnosis. Our data suggest that Amp1q21 is associated with both disease progression and poor prognosis...
- Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression
John Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 101:3849-56. 2003
....
- Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients
Maurizio Zangari
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Blood Coagul Fibrinolysis 18:595-8. 2007
..02). Our observation suggests a possible beneficial effect of anticoagulation on survival in patients treated for myeloma...
- Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience
Athanasios B T Fassas
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 123:484-9. 2003
..In conclusion, a sizeable fraction of myeloma patients relapsing after tandem autotransplants without poor-risk features enjoyed meaningful survival prolongation when appropriately treated...
- The Arkansas approach to therapy of patients with multiple myeloma
Bart Barlogie
Myeloma Institute for Research and Therapy, UAMS, Little Rock, AR, USA
Best Pract Res Clin Haematol 20:761-81. 2007
....
- Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1
Maurizio Zangari
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 141:433-44. 2008
..These results provide a basis for the prospective evaluation of the consolidation strategy in a randomized clinical trial design...
- Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia
Ashraf Badros
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, USA
Leuk Lymphoma 43:1267-71. 2002
..The use of thalidomide should be carefully assessed in relapsed multiple myeloma patients with clinical and cytogenetic evidence of t-MDS...
- Prediction of cytogenetic abnormalities with gene expression profiles
Yiming Zhou
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 119:e148-50. 2012
..The model has an accuracy rate up to 0.89. These results provide proof of concept for the hypothesis that gene expression profiling is a superior genomic method for clinical molecular diagnosis and/or prognosis...
- Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms
Bart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
J Clin Oncol 28:3023-7. 2010
..After further follow-up of 87 months, we examined, in reiterative analyses, the effect of increasing time intervals on clinical outcomes relevant to baseline prognostic variables and treatment randomization...
- First thalidomide clinical trial in multiple myeloma: a decade
Frits van Rhee
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 112:1035-8. 2008
..The poor outcome associated with lambda-type myeloma may relate to its overrepresentation in molecularly defined high-risk disease gleaned from studies in newly diagnosed myeloma...
- Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling
Ya Wei Qiang
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 113:4319-30. 2009
....
- CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms
Fenghuang Zhan
Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham Street, Little Rock, AR 72205, USA
Blood 109:4995-5001. 2007
....
- Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs
Bart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Cancer 112:2720-5. 2008
..Total Therapy (TT) programs are complex and their execution over the course of several years is fraught with patient attrition due to failure and toxicity of therapy and patient/physician acceptance...
- The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells
Simona Colla
Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Blood 109:4470-7. 2007
..We conclude that specific strategies to modulate persistent activation of the JNK pathway may be beneficial in preventing disease progression and treating myeloma-associated bone disease by inhibiting DKK1 expression...
- Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
Maurizio Zangari
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
Br J Haematol 126:715-21. 2004
..The rate of DVT recurrence observed in our study upon thalidomide resumption was sufficiently low to allow its continuation in patients who may benefit from this therapeutic intervention...
- Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
Shmuel Yaccoby
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 109:2106-11. 2007
..We conclude that DKK1 is a key player in MM bone disease and that blocking DKK1 activity in myelomatous bones reduces osteolytic bone resorption, increases bone formation, and helps control MM growth...
- Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
Maurizio Zangari
The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 131:71-3. 2005
..The rise in ALP after bortezomib in three patients was explained by a parallel increase in bone-specific ALP and parathyroid hormone, suggesting that response to bortezomib in myeloma is closely associated with osteoblastic activation...
- Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience
Bart Barlogie
University of Arkansas for Medical Sciences, 4301 W Markham, Slot 623, Little Rock, AR 72205, USA
Semin Hematol 40:33-8. 2003
..These preliminary results corroborate the role for thalidomide and CC-5013 in relapsed/refractory and newly diagnosed multiple myeloma based on the UAMS phase II study as well as several other studies of these agents outside of UAMS...
- Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
John D Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock AR, USA
Blood 118:3512-24. 2011
..We are investigating whether second-generation proteasome inhibitors (eg, carfilzomib) can overcome resistance associated with high PSMD4 levels...
- Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone
Angela Pennisi
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America
PLoS ONE 5:e15233. 2010
..Current management of myeloma bone disease is limited to the use of antiresorptive agents such as bisphosphonates...
- Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance
Saad Z Usmani
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 120:1597-600. 2012
..38; P = .09). These trials are registered at www.clinicaltrials.gov as NCT00573391 (TT2), NCT00081939 (TT3A), and NCT00572169 (TT3B)...
- The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
Angela Pennisi
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 114:1803-12. 2009
..Myeloma cells expressed low to undetectable ephrinB2 and EphB4 and did not respond to the chimeric proteins. The ephrinB2/EphB4 axis is dysregulated in MM, and its activation by EphB4-Fc inhibits myeloma growth and bone disease...
- The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
Erming Tian
Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, College of Medicine, University of Arkansas for Medical Sciences, Little Rock 72205, USA
N Engl J Med 349:2483-94. 2003
..Myeloma cells may secrete factors that affect the function of osteoblasts, osteoclasts, or both...
- Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma
Ya Wei Qiang
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
Br J Haematol 148:726-38. 2010
....
- Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen
Christopher L Morris
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 120:413-23. 2003
..Increasing age adversely affected CD34+ yield even with limited premobilization therapy, indicating that early collection is important in elderly patients...
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D Shaughnessy
Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 109:2276-84. 2007
..Our data suggest that altered transcriptional regulation of genes mapping to chromosome 1 may contribute to disease progression, and that expression profiling can be used to identify high-risk disease and guide therapeutic interventions...
- Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204)
Mohamad A Hussein
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham St, 816, Little Rock, AR 72205, USA
J Clin Oncol 27:3510-7. 2009
..CONCLUSION Both overall survival (P = .0002) and event-free survival (P < .0001) were significantly improved with S0204 compared with S9321 when 121 and 363 patients, respectively, were matched on ISS stage and LDH...
- High-dose therapy and immunomodulatory drugs in multiple myeloma
Bart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Semin Oncol 29:26-33. 2002
..Careful scrutiny of gene expression will also help in the identification of unrecognized targets for therapeutic intervention...
- The role of transplant in multiple myeloma
Bart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Clin Adv Hematol Oncol 3:604-6. 2005
- Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation
Jumei Shi
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 143:641-53. 2008
..Encouragingly, 50% of patients achieved (near) complete remission. These data set the stage for future studies of KIR-ligand mismatched NK cell therapy in the autologous setting...
- Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations
Athanasios B T Fassas
Myeloma and Transplantation Research Center, Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 117:103-8. 2002
..Given this universally poor prognosis, the application of allogeneic transplants should be studied in this clinical setting...
- Recurrent spontaneous gastrointestinal graft-versus-host disease in autologous hematopoietic stem cell transplantation
Somashekar G Krishna
Department of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock 72211, USA
Clin Lymphoma Myeloma Leuk 10:E17-21. 2010
..We report for the first time a patient with spontaneous recurrent GI GVHD after autoHSCT for multiple myeloma with predominant lower GI symptoms and excellent response to enteric-coated budesonide therapy...
- Multiple myeloma: clinical review and diagnostic imaging
Edgardo J C Angtuaco
Department of Radiology and the Myeloma Institute, University of Arkansas for Medical Sciences, 4301 W Markham, Slot 596, Little Rock, AR 72205, USA
Radiology 231:11-23. 2004
..These biopsies have resulted in increased identification of cytogenetic abnormalities, particularly the presence of chromosome 13 deletion, which is a grave prognostic indicator in MM...
- Effects of exercise in combination with epoetin alfa during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for multiple myeloma
Elizabeth A Coleman
Colleges of Medicine and Nursing, University of Arkansas for Medical Sciences, Little Rock, USA
Oncol Nurs Forum 35:E53-61. 2008
..To determine the effect of aerobic and strength resistance training and epoetin alfa (EPO) therapy on transfusions, stem cell collections, transplantation recovery, and multiple myeloma treatment response...
- Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants
Guido Tricot
The Myeloma and Transplantation Research Center and the Division of Biometry, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 116:211-7. 2002
..or = 7 years and re-establishment of a monoclonal gammopathy of undetermined significance (MGUS) phase in those with persistent evidence of disease post transplantation, but without disease progression > or = 7 years...
- Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences
Bart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, 816, Little Rock, AR 72205
J Clin Oncol 28:1209-14. 2010
....
- Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy
Maurizio Zangari
Central Arkansas Veterans Healthcare System and University of Arkansas for Medical Sciences, Little Rock, AR, USA
Blood 100:1168-71. 2002
..02) was observed; this association was confirmed on multivariate analysis. MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT...
- Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning
Ashraf Badros
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
J Clin Oncol 20:1295-303. 2002
..We present our experience with relapsed and recently diagnosed patients with high-risk multiple myeloma (MM) receiving immunosuppressive, nonmyeloablative melphalan (MEL)-based conditioning regimens (mini-allograft)...
- Infection--an underappreciated cause of bone pain in multiple myeloma
Raman Desikan
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Br J Haematol 120:1047-50. 2003
..Previous dexamethasone therapy, together with an episode of bacteraemia, appears to be a predisposing factor for vertebral infection. Magnetic resonance imaging enabled the diagnosis in all three patients...
- A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript
Madhumita Santra
Donna and Donald Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 101:2374-6. 2003
..These data indicate that the t(4;14)(p16;q32) and loss of FGFR3 occurred at a very early stage and suggest that activation of MMSET, not FGFR3, may be the critical transforming event of this recurrent translocation...
- Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling
Fenghuang Zhan
Donna D and m Lambert Laboratory of Myeloma Genetics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Semin Hematol 40:308-20. 2003
..Here we discuss recent progress made in the development of molecular-based diagnostics and prognostics for MM through the dissection of the transcriptome of PCs from healthy individuals and patients with MM and other PC dyscrasias...
- Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma
Athanasios B T Fassas
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 118:1041-7. 2002
..Furthermore, these parameters in combination with easily obtained pretransplant levels of beta-2 microglobulin and albumin define three groups of MM patients with clearly distinct outcomes...
- The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management
Elias J Anaissie
Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock 72205, USA
Blood 103:1611-7. 2004
..RSV infection may not necessarily be a contraindication for APBSCT or an indication for therapy with aerosolized ribavirin and IVIG...
- Diagnosis of infection of implantable central venous catheters by [18F]fluorodeoxyglucose positron emission tomography
Marisa H Miceli
The University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, Arkansas, USA
Nucl Med Commun 25:813-8. 2004
..FDG PET may help prevent the unnecessary removal of implantable intravascular catheters and the unwarranted use of antibiotics...
- Morphologic heterogeneity of renal light-chain deposition disease
Neriman Gokden
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Ultrastruct Pathol 32:17-24. 2008
..Immunofluorescence is more sensitive than EM for detection of LC for the definitive diagnosis of LCDD. This study supports the importance of utilizing kappa and lambda stains in the routine IF panel for diagnosis of LCDD...
- Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients
James R Berenson
Cedars Sinai Medical Center and the Jonsson Comprehensive Cancer Center, University of California-Los Angeles, USA
Blood 99:3163-8. 2002
..Thus, 50 mg, oral, alternate-day prednisone is effective maintenance treatment for multiple myeloma patients who achieve a response to induction chemotherapy. (Blood. 2002;99:3163-3168)..
- Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function
Sundar Jagannath
Blood Stem Cell and Bone Marrow Transplantation, St Vincent s Comprehensive Cancer Center, New York, New York 10011 8202, USA
Cancer 103:1195-200. 2005
..Bortezomib is a potent, reversible proteasome inhibitor that has been approved for the treatment of recurrent and/or refractory multiple myeloma, but its activity in patients with renal impairment has not been studied to date...
- Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy
Guido Tricot
University of Utah School of Medicine, 30N 1900E, 5C402, Salt Lake City, UT 84132 USA
Haematologica 93:1739-42. 2008
..001) and (v) platelet recovery was faster after first transplant (when less stem cells were infused) (p=0.01). Pegfilgrastim may be considered the standard of care for stem cell mobilization...
- Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling
Jeffrey Haessler
Cancer Research and Biostatistics, Seattle, Washington, USA
Clin Cancer Res 13:7073-9. 2007
..To determine whether the clinical benefit of complete remission (CR) may depend on prognostic subgroups of patients with multiple myeloma...
- Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone
Sundar Jagannath
St Vincent s Comprehensive Cancer Center, 325 West 15th Street, New York, NY, USA
Haematologica 91:929-34. 2006
..BACKGROUND AND OBJECTIVEs: The efficacy and safety of added dexamethasone were assessed in patients with relapsed and/or refractory multiple myeloma who had a suboptimal response to bortezomib alone...
- Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
Heinz Ludwig
Department of Medicine, Wilhelminenspital, Montleartstr 37, 1160 Vienna, Austria
Blood 111:4039-47. 2008
....
- Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials
Brian G M Durie
Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
J Clin Oncol 22:1857-63. 2004
..The purpose was to clarify the predictive value of specific levels of myeloma-associated monoclonal protein reduction and time to first progression using mature data sets...
- Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy
Radek Spisek
Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA
J Exp Med 204:831-40. 2007
..Harnessing immunity to antigens expressed by tumor progenitor cells may be critical for prevention and therapy of human cancer...
- High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis
Frits van Rhee
Blood 110:827-32. 2007
..65, P = .003). Unlike baseline and follow-up analyses of serum and urine M-proteins, high SFLC levels at baseline-reflecting more aggressive disease-and steeper reductions after therapy identified patients with inferior survival...
- Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis
Jeffrey A Zonder
Blood 108:403; author reply 404. 2006
- High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients
Daniel R Carrasco
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Cell 9:313-25. 2006
....
- Highlights from the 46 th annual meeting of the American Society of Hematology
Athanasios Fassas
Clin Adv Hematol Oncol 3:111-6. 2005
- A phase 2 study of bortezomib in relapsed, refractory myeloma
Paul G Richardson
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
N Engl J Med 348:2609-17. 2003
..Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has been shown in preclinical and phase 1 studies to have antimyeloma activity...
- Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma
Sagar Lonial
Winship Cancer Institute, Emory University, Atlanta, GA, USA
Blood 106:3777-84. 2005
..The exact mechanism underlying bortezomib-induced thrombocytopenia remains unknown but it is unlikely to be related to marrow injury or decreased thrombopoietin production...
- Duration of survival in patients with myeloma treated with thalidomide
Bart Barlogie
N Engl J Med 359:210-2. 2008
- MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants
Joth Jacobson
Cancer Research and Biostatistics, Seattle, WA 98101 1468, USA
Br J Haematol 122:430-40. 2003
....
- A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience
Joth L Jacobson
Southwest Oncology Group Statistical Center, Seattle, WA 98101 1468, USA
Br J Haematol 122:441-50. 2003
..Additional evaluation in other MM patient populations is needed to confirm results...
